The MIR100HG/hnRNPA2B1/TCF7L2 axis was augmented in specimens from CRC patients who either developed local or distant metastasis or had disease progression that was associated with cetuximab resistance. This evidence concerns the gene HNRNPA2B1 and colorectal carcinoma.